Akebia Therapeutics (AKBA) SVP granted 190K RSUs and options

Rhea-AI Filing Summary

Akebia Therapeutics SVP and Chief Legal Officer Carolyn M. Rucci reported new equity awards. On January 30, 2026, she received 190,000 shares of common stock in the form of restricted stock units at $0.00 per share, bringing her directly held common stock to 658,150 shares.

She was also granted a stock option for 270,000 shares of common stock with a $1.41 exercise price, all held directly. The restricted stock units vest in three equal annual installments, while the options vest over four years, both subject to continued service with the company.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Rucci Carolyn M.

Role SVP, Chief Legal Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to buy)	270,000	$0.00	--
Grant/Award	Common Stock	190,000	$0.00	--

Holdings After Transaction: Stock Option (Right to buy) — 270,000 shares (Direct); Common Stock — 658,150 shares (Direct)

Footnotes (1)

1. The restricted stock units were granted by the Issuer pursuant to its 2023 Stock Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date. The options were granted by the Issuer pursuant to its 2023 Stock Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rucci Carolyn M.

(Last) (First) (Middle)

C/O AKEBIA THERAPEUTICS, INC

245 FIRST ST.

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Akebia Therapeutics, Inc. [ AKBA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/30/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/30/2026		A		190,000(1)	A	$0.00	658,150	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to buy)	$1.41	01/30/2026		A		270,000		(2)	01/30/2036	Common Stock	270,000	$0.00	270,000	D

Explanation of Responses:

1. The restricted stock units were granted by the Issuer pursuant to its 2023 Stock Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date.

2. The options were granted by the Issuer pursuant to its 2023 Stock Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date.

Remarks:

	/s/ Carolyn M. Rucci	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider equity awards were reported for Akebia Therapeutics (AKBA)?

Akebia Therapeutics reported new equity grants to SVP and Chief Legal Officer Carolyn M. Rucci. She received 190,000 restricted stock units and a stock option for 270,000 shares, both granted on January 30, 2026 under the company’s 2023 Stock Incentive Plan.

How many Akebia Therapeutics (AKBA) shares does Carolyn Rucci now beneficially own?

After the reported transaction, Carolyn Rucci beneficially owns 658,150 shares of Akebia common stock directly. This figure reflects her holdings following the grant of 190,000 restricted stock units reported as acquired at a price of $0.00 per share.

What are the vesting terms for Carolyn Rucci’s restricted stock units at Akebia (AKBA)?

The 190,000 restricted stock units vest in three equal annual installments. One third will vest on each of the first, second, and third anniversaries of the January 30, 2026 grant date, contingent on her continued service with Akebia on each vesting date.

What are the key terms of the stock options granted to Carolyn Rucci by Akebia (AKBA)?

The stock option covers 270,000 shares of Akebia common stock at a $1.41 exercise price. It vests over four years: 25% on the first anniversary of the January 30, 2026 grant date, and the remaining 75% in equal quarterly installments thereafter, subject to continued service.

Why did Akebia Therapeutics (AKBA) file this insider trading report?

The filing reports equity compensation granted to an executive officer. It discloses that SVP and Chief Legal Officer Carolyn M. Rucci received restricted stock units and stock options under Akebia’s 2023 Stock Incentive Plan, documenting amounts, terms, and her resulting beneficial ownership.

Under which plan were Carolyn Rucci’s new Akebia (AKBA) awards granted?

Both the restricted stock units and stock options were granted under Akebia’s 2023 Stock Incentive Plan, as amended. The footnotes specify that this plan governs the awards and their multi-year vesting schedules, each conditioned on her continued service with the company.